HIQA publishes assessment of adding classic congenital adrenal hyperplasia to the National Newborn Bloodspot Screening Programme
Today, the Health Information and Quality Authority (HIQA) has published a health technology assessment examining the potential addition of classic congenital adrenal hyperplasia (CAH) to Ireland’s National Newborn Bloodspot Screening Programme, commonly known as the ‘heel prick’ test. The assessment was undertaken to inform the National Screening Advisory Committee’s recommendation on whether screening for this condition should be introduced.
Following a positive recommendation from National Screening Advisory Committee, the Minister for Health has approved the addition of CAH to the National Newborn Bloodspot Screening Programme.
Classic CAH is a rare inherited condition that affects approximately four babies born in Ireland each year. Around three in four affected babies have the salt-wasting form of the condition. Babies with salt-wasting CAH lose too much salt and water from their body, which can lead to a life-threatening adrenal crisis if not detected and treated promptly.
The assessment found that screening has the potential to identify babies with salt-wasting CAH before they have an adrenal crisis in the neonatal period. Screening may be particularly beneficial for male infants who typically do not show signs of the condition at birth and are therefore at greater risk of delayed diagnosis.
Important considerations were identified regarding the accuracy of the screening test, particularly for premature babies, and the need to ensure that screening results are available before serious illness develops. Expanding the National Newborn Bloodspot Screening Programme would require additional laboratory capacity, programme resources, and updates to supporting infrastructure.
Commenting on the findings, HIQA’s Deputy Chief Executive and Director of Health Technology Assessment, Dr Máirín Ryan, said:
“Newborn bloodspot screening aims to identify rare but serious conditions before serious and irreversible complications occur. Our assessment found that screening for classic CAH has the potential to identify affected babies earlier and reduce the risk of a life-threatening adrenal crisis.”
Dr Ryan continued: “There is some uncertainty about how much benefit screening would provide. This is mainly because classic CAH is a rare disease and there is limited data on how often serious outcomes occur under current practice. This is a challenge that we frequently face when assessing newborn bloodspot screening for rare diseases.”
Overall, the assessment concludes that adding CAH to the National Newborn Bloodspot Screening Programme has the potential to deliver clinical benefits, provided appropriate laboratory, clinical and programme resources are available to support timely testing, reporting and referral pathways.
ENDS
Notes:
- The National Screening Advisory Committee was established in 2019 as an independent advisory committee to advise the Minister and Department of Health on all new proposals for population-based screening programmes and revisions to existing programmes. Further information on the NSAC is available here.
- The National Newborn Bloodspot Screening Programme, commonly known as the ‘heel prick’ test, is offered to all newborn babies in Ireland. With parental or guardian consent, a blood sample is usually collected between 72 and 120 hours after birth.
- The National Newborn Bloodspot Screening Programme currently screens newborn babies in Ireland for 11 rare but serious conditions. Two conditions, severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA) were added to the newborn screening panel in April 2026.
- CAH occurs along a spectrum of disease severity, ranging from classic CAH to the milder non-classic form. Available screening tests are not sensitive enough to reliably detect non-classic CAH. As a result, the scope of this assessment was limited to classic CAH.
- HIQA found that newborn screening for CAH is widely established internationally.
- The report highlights the importance of designing the screening pathway to ensure babies with classic CAH are identified and referred quickly, while minimising unnecessary follow-up testing, particularly in premature babies. International evidence indicates that reporting by day 10 of life may be important to maximise the clinical benefits of screening.
About HIQA
The Health Information and Quality Authority (HIQA) is the independent body that promotes safety and quality in the provision of health and social care services in Ireland. Through its regulation, standard setting and evidence to inform decision-making functions, HIQA supports health and social care services to consistently deliver excellent standards of care and the best possible health and social care outcomes for all.